{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:50:21Z","timestamp":1791406221289,"version":"4.3.3"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.det.2018.12.008","type":"journal-article","created":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T01:54:30Z","timestamp":1550282070000},"page":"175-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["What\u2019s New in Pigmentary Disorders"],"prefix":"10.1016","volume":"37","author":[{"given":"Raheel","family":"Zubair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis B.","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautham","family":"Vellaichamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjelica","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.det.2018.12.008_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1473-2165.2008.00384.x","article-title":"Prevalence of pigmentary disorders and their impact on quality of life: a prospective cohort study","volume":"7","author":"Taylor","year":"2008","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.12.008_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamadermatol.2014.1875","article-title":"Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial","volume":"151","author":"Lim","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.008_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0190-9622(92)70024-A","article-title":"Autologous grafting with noncultured melanocytes: a simplified method for treatment of depigmented lesions","volume":"26","author":"Gauthier","year":"1992","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.008_bib4","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.jisp.2017.01.001","article-title":"Vitiligo surgery: shuffling melanocytes","volume":"18","author":"Nahhas","year":"2017","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"issue":"5","key":"10.1016\/j.det.2018.12.008_bib5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jaad.2011.05.002","article-title":"Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: the experience of an academic medical center in the United States","volume":"66","author":"Huggins","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.12.008_bib6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12007","article-title":"Comparison between autologous noncultured epidermal cell suspension and suction blister epidermal grafting in stable vitiligo: a randomized study","volume":"167","author":"Budania","year":"2012","journal-title":"Br J Dermatol"},{"issue":"Suppl 4","key":"10.1016\/j.det.2018.12.008_bib7","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/S0039-6257(01)00224-7","article-title":"The pharmacology of bimatoprost (Lumigan)","volume":"45","author":"Woodward","year":"2001","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"10.1016\/j.det.2018.12.008_bib8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.bjp.0707434","article-title":"Prostamides (prostaglandin-ethanolamides) and their pharmacology","volume":"153","author":"Woodward","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.det.2018.12.008_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12409","article-title":"Efficacy of bimatoprost in the treatment of non-facial vitiligo","volume":"30","author":"Bagherani","year":"2017","journal-title":"Dermatol Ther"},{"issue":"11","key":"10.1016\/j.det.2018.12.008_bib10","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archopht.123.11.1541","article-title":"Bimatoprost-induced periocular skin hyperpigmentation: histopathological study","volume":"123","author":"Kapur","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.det.2018.12.008_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1468-3083.2009.03346.x","article-title":"Skin pigmentation after NB-UVB and three analogues of prostaglandin F(2alpha) in guinea pigs: a comparative study","volume":"24","author":"Anbar","year":"2010","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.det.2018.12.008_bib12","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/jdv.13176","article-title":"Bimatoprost in periorbital vitiligo: a ray of hope or dilemma","volume":"30","author":"Jha","year":"2016","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.det.2018.12.008_bib13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/ced.12904","article-title":"Bimatoprost in vitiligo","volume":"41","author":"Jha","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.det.2018.12.008_bib14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jocd.12443","article-title":"Bimatoprost ophthalmic solution in facial vitiligo","volume":"17","author":"Jha","year":"2018","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.12.008_bib15","first-page":"703","article-title":"Bimatoprost 0.03% solution for the treatment of nonfacial vitiligo","volume":"15","author":"Grimes","year":"2016","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"10","key":"10.1016\/j.det.2018.12.008_bib16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/bjo.2007.128454","article-title":"Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4","volume":"92","author":"Williams","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.det.2018.12.008_bib17","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","article-title":"One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension","volume":"120","author":"Higginbotham","year":"2002","journal-title":"Arch Ophthalmol"},{"issue":"223","key":"10.1016\/j.det.2018.12.008_bib18","doi-asserted-by":"crossref","first-page":"223ra223","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.det.2018.12.008_bib19","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.12.008_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.12.008_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/eci.12.19","article-title":"Tofacitinib for the treatment of rheumatoid arthritis","volume":"8","author":"Zerbini","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.det.2018.12.008_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrd3652","article-title":"Ruxolitinib","volume":"11","author":"Mesa","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.det.2018.12.008_bib23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.12.008_bib24","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.12.008_bib25","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.jaad.2018.02.023","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B","volume":"78","author":"Joshipura","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.12.008_bib26","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.12.008_bib27","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: a systematic review","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.det.2018.12.008_bib28","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/jid.2010.95","article-title":"Impact of long-wavelength UVA and visible light on melanocompetent skin","volume":"130","author":"Mahmoud","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2018.12.008_bib29","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1473-2165.2007.00288.x","article-title":"A\u00a0comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma","volume":"6","author":"Ferreira Cestari","year":"2007","journal-title":"J\u00a0Cosmet Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.008_bib30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/0019-5154.108070","article-title":"A\u00a0comparative study of the efficacy of 4% hydroquinone vs 0.75% kojic acid cream in the treatment of facial melasma","volume":"58","author":"Monteiro","year":"2013","journal-title":"Indian J Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.12.008_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4103\/0019-5154.113940","article-title":"Kojic acid vis-a-vis its combinations with hydroquinone and betamethasone valerate in melasma: a randomized, single blind, comparative study of efficacy and safety","volume":"58","author":"Deo","year":"2013","journal-title":"Indian J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.12.008_bib32","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/DSS.0000000000001518","article-title":"Oral tranexamic acid for the treatment of melasma: a review","volume":"44","author":"Bala","year":"2018","journal-title":"Dermatol Surg"},{"issue":"13","key":"10.1016\/j.det.2018.12.008_bib33","first-page":"3129","article-title":"Treatment of melasma with tranexamic acid","author":"Sadako","year":"1979","journal-title":"Clin Rep"},{"issue":"4","key":"10.1016\/j.det.2018.12.008_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3109\/09546634.2011.643220","article-title":"Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd: YAG laser","volume":"24","author":"Cho","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"3","key":"10.1016\/j.det.2018.12.008_bib35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/jdv.12209","article-title":"Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial","volume":"28","author":"Li","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3 Pt 1","key":"10.1016\/j.det.2018.12.008_bib36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/dsu.12060","article-title":"Oral tranexamic acid enhances the efficacy of low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet laser treatment for melasma in Koreans: a randomized, prospective trial","volume":"39","author":"Shin","year":"2013","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.det.2018.12.008_bib37","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00266-012-9899-9","article-title":"Treatment of melasma with oral administration of tranexamic acid","volume":"36","author":"Wu","year":"2012","journal-title":"Aesthetic Plast Surg"},{"issue":"8","key":"10.1016\/j.det.2018.12.008_bib38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1468-3083.2012.04464.x","article-title":"Effect of tranexamic acid on melasma: a clinical trial with histological evaluation","volume":"27","author":"Na","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.det.2018.12.008_bib39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4103\/0019-5154.164416","article-title":"Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: an open labeled randomized comparative trial","volume":"60","author":"Padhi","year":"2015","journal-title":"Indian J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.008_bib40","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2016.03.001","article-title":"Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis","volume":"75","author":"Lee","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2018.12.008_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2017.09.053","article-title":"Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma","volume":"78","author":"Del Rosario","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2018.12.008_bib42","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1248\/jhs.53.389","article-title":"Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium","volume":"53","author":"Maeda","year":"2007","journal-title":"J\u00a0Health Sci"},{"issue":"9","key":"10.1016\/j.det.2018.12.008_bib43","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1524-4725.1994.tb00152.x","article-title":"Ineffective treatment of refractory melasma and postinflammatory hyperpigmentation by Q-switched ruby laser","volume":"20","author":"Taylor","year":"1994","journal-title":"J\u00a0Dermatol Surg Oncol"},{"issue":"12","key":"10.1016\/j.det.2018.12.008_bib44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1524-4725.1994.tb03707.x","article-title":"The removal of cutaneous pigmented lesions with the Q-switched ruby laser and the Q-switched neodymium: yttrium-aluminum-garnet laser. A comparative study","volume":"20","author":"Tse","year":"1994","journal-title":"J\u00a0Dermatol Surg Oncol"},{"key":"10.1016\/j.det.2018.12.008_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/2047-783X-18-43","article-title":"Treatment of melasma in Caucasian patients using a novel 694-nm Q-switched ruby fractional laser","volume":"18","author":"Hilton","year":"2013","journal-title":"Eur J Med Res"},{"issue":"8","key":"10.1016\/j.det.2018.12.008_bib46","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1524-4725.2011.02018.x","article-title":"Efficacy of 694-nm Q-switched ruby fractional laser treatment of melasma in female Korean patients","volume":"37","author":"Jang","year":"2011","journal-title":"Dermatol Surg"},{"issue":"7","key":"10.1016\/j.det.2018.12.008_bib47","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/lsm.22263","article-title":"A\u00a0randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma","volume":"46","author":"Fabi","year":"2014","journal-title":"Lasers Surg Med"},{"issue":"8","key":"10.1016\/j.det.2018.12.008_bib48","doi-asserted-by":"crossref","first-page":"e847","DOI":"10.1111\/j.1365-2230.2009.03599.x","article-title":"Melasma treatment in Korean women using a 1064-nm Q-switched Nd: YAG laser with low pulse energy","volume":"34","author":"Cho","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"10.1016\/j.det.2018.12.008_bib49","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/14764172.2011.630084","article-title":"Treatment of Melasma with low fluence, large spot size, 1064-nm Q-switched neodymium-doped yttrium aluminum garnet (Nd: YAG) laser for the treatment of melasma in Fitzpatrick skin types II\u2013IV","volume":"13","author":"Brown","year":"2011","journal-title":"J\u00a0Cosmet Laser Ther"},{"issue":"1","key":"10.1016\/j.det.2018.12.008_bib50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1524-4725.2009.01383.x","article-title":"Low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser for the treatment of facial melasma in Asians","volume":"36","author":"Wattanakrai","year":"2010","journal-title":"Dermatol Surg"},{"issue":"4","key":"10.1016\/j.det.2018.12.008_bib51","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5978\/islsm.17-RE-02","article-title":"Picosecond laser treatment for tattoos and benign cutaneous pigmented lesions (secondary publication)","volume":"26","author":"Kasai","year":"2017","journal-title":"Laser Ther"},{"issue":"3","key":"10.1016\/j.det.2018.12.008_bib52","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/14764172.2017.1376098","article-title":"Effects of a fractional picosecond 1,064 nm laser for the treatment of dermal and mixed type melasma","volume":"20","author":"Chalermchai","year":"2018","journal-title":"J\u00a0Cosmet Laser Ther"},{"issue":"10","key":"10.1016\/j.det.2018.12.008_bib53","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/lsm.22735","article-title":"Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: a prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial","volume":"49","author":"Choi","year":"2017","journal-title":"Lasers Surg Med"},{"issue":"10","key":"10.1016\/j.det.2018.12.008_bib54","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1468-3083.2009.03123.x","article-title":"Treatment of post-inflammatory hyperpigmentation using 1064-nm Q-switched Nd:YAG laser with low fluence: report of three cases","volume":"23","author":"Cho","year":"2009","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"11","key":"10.1016\/j.det.2018.12.008_bib55","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1111\/j.1524-4725.2009.01303.x","article-title":"Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation","volume":"35","author":"Katz","year":"2009","journal-title":"Dermatol Surg"},{"issue":"3","key":"10.1016\/j.det.2018.12.008_bib56","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1524-4725.2009.01090.x","article-title":"Fractional photothermolysis for the treatment of postinflammatory hyperpigmentation after carbon dioxide laser resurfacing","volume":"35","author":"Rokhsar","year":"2009","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.det.2018.12.008_bib57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jaad.2013.09.017","article-title":"Reliability assessment and validation of the postacne hyperpigmentation index (PAHPI), a new instrument to measure postinflammatory hyperpigmentation from acne vulgaris","volume":"70","author":"Savory","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518311501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863518311501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:42:07Z","timestamp":1760006527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863518311501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0733863518311501"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2018.12.008","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What\u2019s New in Pigmentary Disorders","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2018.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}